Publications

Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.

Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.

See below for some of our recent publications.

Scenesse (Afamelanotide) for Erythropoietic Protoporphyria

Scenesse is a subcutaneous implant containing a synthetic analog of alpha-melanocyte stimulating hormone. It is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.

Scenesse (Afamelanotide) for Erythropoietic Protoporphyria

Scenesse is a subcutaneous implant containing a synthetic analog of alpha-melanocyte stimulating hormone. It is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.

Balloon Sinuplasty for Chronic Sinusitis in Pediatric Patients

Health Problem: Pediatric chronic rhinosinusitis (PCRS) affects from 1.7 to 4.4 million children in the United States and is associated with an estimated annual expenditure of $1.8 billion. PCRS places a large burden of morbidity on children due to persistent symptoms, impaired sleep, multiple hospital visits, medication usage, and missed sch…

Endari (Pharmaceutical Grade L-Glutamine)

Endari (oral pharmaceutical grade L-glutamine) is an amino acid with antioxidant properties indicated to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. It is a precursor for nicotinamide adenine dinucleotide (NAD), which is deficient in patients with SCD. A definitive mechanism of action is not yet defined…

Endari (Pharmaceutical Grade L-Glutamine)

Endari (oral pharmaceutical grade L-glutamine) is an amino acid with antioxidant properties indicated to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. It is a precursor for nicotinamide adenine dinucleotide (NAD), which is deficient in patients with SCD. A definitive mechanism of action is not yet defined…

Balloon Sinuplasty for Treatment of Chronic Rhinosinusitis in Adult Patients

Health Problem: Chronic rhinosinusitis (CRS), which is the symptomatic inflammation of sinonasal mucosa, is one of the most prevalent chronic conditions, impacting from 5% to 15% of adults and costing the United States an estimated $6.9 to $9.9 billion per year. Differentiating CRS and recurrent acute rhinosinusitis (RARS) is challenging, so …

Stereotactic Radiosurgery for Trigeminal Neuralgia

Health Problem: Trigeminal neuralgia (TGN) is a neurological condition that can cause severe pain that cannot be controlled with medication in some patients. Women are twice as likely to be affected as men and the disease most often presents after age 40 years, with a typical age of onset between 60 to 70 years.